356 related articles for article (PubMed ID: 30404927)
1. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract][Full Text] [Related]
2. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
3. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
4. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
[TBL] [Abstract][Full Text] [Related]
5. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
6. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
8. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
9. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer.
Mehra S; Garrido VT; Dosch AR; Lamichhane P; Srinivasan S; Singh SP; Zhou Z; De Castro Silva I; Joshi C; Ban Y; Datta J; Gilboa E; Merchant NB; Nagathihalli NS
Cancer Res Commun; 2023 Jul; 3(7):1224-1236. PubMed ID: 37448553
[TBL] [Abstract][Full Text] [Related]
10. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
11. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract][Full Text] [Related]
12. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
13. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer.
Mortazavi M; Moosavi F; Martini M; Giovannetti E; Firuzi O
Crit Rev Oncol Hematol; 2022 Aug; 176():103749. PubMed ID: 35728737
[TBL] [Abstract][Full Text] [Related]
14. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G
Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560
[TBL] [Abstract][Full Text] [Related]
15. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
Mohammed A; Qian L; Janakiram NB; Lightfoot S; Steele VE; Rao CV
Int J Cancer; 2012 Oct; 131(8):1951-62. PubMed ID: 22287227
[TBL] [Abstract][Full Text] [Related]
17. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR prosurvival signaling.
Deeb D; Gao X; Liu Y; Zhang Y; Shaw J; Valeriote FA; Gautam SC
Int J Oncol; 2016 Sep; 49(3):1139-47. PubMed ID: 27573873
[TBL] [Abstract][Full Text] [Related]
19. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
20. Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model.
Siddique HR; Liao DJ; Mishra SK; Schuster T; Wang L; Matter B; Campbell PM; Villalta P; Nanda S; Deng Y; Saleem M
Int J Cancer; 2012 Oct; 131(7):1720-31. PubMed ID: 22190076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
